Addex Therapeutics Ltd. (ADXN) company profile
Close on Nov 18, 2026Market cap $62.83KP/E –Yield –
About Addex Therapeutics
Pharmaceutical Preparations, SIC 2834
Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company focused on discovering and developing orally available small molecule drug candidates. The company specializes in allosteric modulators targeting G-protein coupled receptors to treat conditions with high unmet medical needs. Its proprietary development pipeline includes dipraglurant for brain injury and post-stroke sensorimotor recovery, ADX71149 for evaluated neurological indications, and positive allosteric modulator programs targeting chronic cough and substance use disorders. Rather than selling directly to commercial consumers, the company advances candidates through internal programs or licenses them to pharmaceutical partners, such as Indivior.
The company operates internationally with its corporate headquarters and principal executive offices located in Geneva, Switzerland, alongside an additional investor contact office in the United States. Its operations include proprietary clinical and preclinical development programs supported by patent portfolios covering the United States, Europe, and Japan.
Summary of the business section of Addex Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Addex Therapeutics Ltd.
- Founded
- 2002
- Headquarters
- Geneva, V8
- Address
- Chemin Des Mines 9 CH-1202
- Phone
- 01141228841555
- Website
- addextherapeutics.com
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- BDO AG, Zurich, Switzerland
Stock & identifiers
- Ticker
- ADXN
- Exchange
- Nasdaq
- IPO date
- Jan 28, 2020
- Shares outstanding
- 148M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-20 reverse, Oct 23, 2023
- SEC CIK
- 1574232
- CUSIP
- 00654J206
- ISIN
- US00654J2069
- FIGI
- BBG00R48ST95
- Share class FIGI
- BBG00R48SV18
- LEI
- 89450068Y9KVP2MQGH86
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Timothy Mark Dyer | CHIEF EXECUTIVE OFFICER, Director | 435,192 |
| Roger Mills | CHIEF MEDICAL OFFICER, Director | 785,976 |
| Lenaic Nathanael Teyssedou | PRINCIPAL ACCOUNTING OFFICER | – |
| Mikhail Kalinichev | HEAD OF TRANSLATIONAL SCIENCE | 0 |
| Vincent Michael Lawton | Director | 2,507,987 |
| Raymond George Hill | Director | 0 |
| Jason Raleigh Nunn | Director | 219,561 |
| Isaac Manke | Director | 219,561 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 28, 2020
- Securities offered
- 11,553,190
- Exchange
- Nasdaq
- First trading day
- Jan 29, 2020
- First-day close
- $14.50
- Lock-up ends (est.)
- Jul 27, 2020
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We had 3 full-time employees as of December 31, 2025 compared to 2 at December 31, 2024.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2026 | Late filing | Notification of late filing |
| Apr 30, 2025 | Late filing | Notification of late filing |
| Jan 28, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 14, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?